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MR angiography with blood pool
contrast agents
Abstract Contrast-enhanced magnet-
ic resonance angiography (CE-MRA)
with standard extracellular contrast
material is well established for vascu-
lar imaging. Recently, the first blood
pool contrast agent (BPA) has become
clinically available. This paper re-
views characteristics and classification
of BPA as well as first clinical expe-
rience in various vascular territories.
BPAs comprise gadolinium-based
compounds, synthetic compounds,
and ultrasmall superparamagnetic
iron-oxide (USPIO) particles. Such
BPAs are retained in blood with a
prolonged time-window of enhance-
ment as compared to extracellular
gadolinium chelates. Promising re-
sults from USPIO at first-pass and
steady-state angiography have been
published, but no USPIO is approved
yet. Gadofosveset is the first clinically
approved BPA. After bolus injection,
gadofosveset binds noncovalently to
serum-albumine, thus enhancing re-
laxivity. First published results from
carotid, coronary, renal, and peripheral
angiography are encouraging; partic-
ularly helpful is prolonged enhance-
ment during steady state. More BPAs
have been clinically evaluated, but no
approval has been granted. Bolus-
injectable BPAs allow for first-pass
CE-MRA similar to standard extra-
cellular contrast media, but with
higher relaxivity, allowing lower
doses and reduced injection rates. An
additional feature of BPA is the steady-
state phase with a broad time window
enabling high-resolution angiography
or double-gated angiography of coro-
nary arteries to compensate for the
complex motion pattern.
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Introduction
Contrast-enhanced magnetic resonance angiography (CE-
MRA) is well established for the diagnosis and manage-
ment of vascular disease. Magnetic resonance angiography
does not necessarily require contrast material, but CE-
MRA has become the standard of practice because it is
faster and flow independent. It is more reproducible, less
operator dependent, has a larger field of view, and higher
contrast than duplex sonography [1]. In patients with
normal renal function [2], CE-MRA offers a safe alterna-
tive to computed tomography, because it requires neither
ionizing radiation nor iodinated contrast media. In patients
with renal failure, however, acquisition of CE-MRA has to
be considered with caution, since exposure to gadolinium-
based contrast material may be complicated by nephro-
genic systemic fibrosis [3]. CE-MRA can be supplemented
with time-resolved angiography, flow measurement, vessel
wall imaging, and plaque characterization for a more
comprehensive assessment of vascular disease.
Standard extracellular contrast media are currently used for
almost all CE-MRA applications. Angiography during the
first pass provides strong and selective enhancement of the
vessel of interest. During steady state, however, angiography
is not useful because of rapid extravasation of such extracel-
lular contrast media resulting in decreasing vascular and
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increasing background signal. Thus, precise bolus timing and
patient cooperation are mandatory for such CE-MRA.
Recently, a new generation of contrast agents with
intravascular distribution, also refered to as blood pool
agents (BPA), has become available. Among the class of
contrast agents that provides strong and prolonged vascular
enhancement, one preparation, gadofosveset (Vasovist®,
Bayer Schering Pharma, Germany), has been approved for
clinical use.
This paper reviews the classification and characteristics of
BPA as well as first clinical experience in various vascular
territories with the first clinically approved compound.
Classification of BPA
Contrast agents that reduce the T1 relaxivity of blood
increase intravascular signal. The use of intravenous low and
high molecular gadolinium chelates for CE-MRA is limited
by the rapid equilibration of these agents among the
intravascular, extravascular, and extracellular compartments.
Whether this actually leads to relevant disadvantages
remains to be proven. In theory,MR contrast agents confined
to the intravascular space may change the way vessels are
currently imaged by means of CE-MRA. Furthermore, if
these agents would also exhibit a prolonged plasma half-life,
additional applications within the field of CE-MRA, but also
beyond angiography may open new applications. Blood-
pool agents are particularly promising in contrasting smaller
vessels, vessels with slow flow, and vessels with complex
flow. In addition, blood-pool agents may be used for
perfusion imaging, functional imaging, imaging in various
anatomic positions (Fig. 1), detection of gastrointestinal
bleeding, or tumor imaging such as the demonstration of
angiogenesis [4, 5]. Several approaches of BPA have been
tested such as supraparamagnetic ultrasmall iron-oxides
particles [6, 7], paramagnetic gadolinium-based macro-
molecules [8, 9], and gadolinium-based small molecules
with reversible protein binding [10, 11].
Whereas the design of iron oxides suited for blood-pool
imaging is well understood and developed, a variety of
gadolinium-based agents with different pharmacological
profiles is under development (Table 1). The initial devel-
opment of blood-pool agents focused on macromolecules
with high relaxivity based on the slow rotation of these
molecules in blood. Different molecules were evaluated such
as albumin, dextran, polylysine, and polymers [12–14].
Concerns linger about the potential immunogenicity and
excretion of these agents, particularly after repeated injec-
tions [15]. Gadobenate dimeglumine (Multihance®, Bracco,
Italy) also exhibits some weak protein binding, which
increases intravascular signal at contrast-enhanced MRA
[16]. Some of the agents with synthetic molecules/polymers
exhibiting different blood half-lives are under experimental
or clinical development. There are two blood-pool agents
with completed clinical trials. The most advanced agent with
a filed FDA application and approval in the EuropeanUnion,
Switzerland, Canada, and Australia is gadofosveset trisodi-
um, formerly identified with the code nameMS-325 [10, 11]
(Fig. 2). The ultrasmall iron-oxide (USPIO) particle SH U
555 C (Supravist®, Bayer Schering Pharma, Germany) is
derived from Ferucarbotran [7, 17, 18].
Iron oxide BPA
Iron-based blood pool agents are coated ultrasmall super-
paramagnetic iron-oxide particles (USPIO) with a strong
T1 and T2 shortening effect. Such compounds are retained
within the intravascular space in a prolonged fashion.USPIOs
Fig. 1 A 43-year-old female
with stenosis of the subclavian
artery (arrow) and vein (arrow-
head) when arms are elevated.
Targeted maximum intensity
projection of CE-MRA shows
strong selective arterial en-
hancement during first pass of
gadofosvesit trisodium
(0.03 mmol/kg @ 0.8 ml/s) (a)
and prolonged arterial/venous
enhancement during steady state
(b). Moreover, the long time
window of vascular enhance-
ment allows steady-state
imaging with arms down (c),
showing release of the arterial
and venous compression.
(Courtesy of Dr. Heyder, Grabs,
Switzerland)
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have a particle size of approximately 20 nm and are smaller
than superparamagnetic iron-oxide particles (SPIO) used for
liver imaging [ferumoxides in Endorem® (Guerbet, France)
Feridex® (Bayer Schering Pharma, Germany) or ferucarbo-
tran in Resovist® (Bayer Schering Pharma, Germany)].
Superparamagnetic particles (SPIO) with predominant T2
shortening effect have also been referred to as BPA, but have
very short vascular half-lives of less than 10 min due to
endocytosis in the liver, spleen and other RES tissues. On T1-
weighted pulse sequences USPIO-enhanced vessels appear
bright. Sequences with short echo times are required to
minimize confounding susceptibility effects. Examples for
USPIO are NC100150 Injection (Clariscan®, development
discontinued) [19], ferumoxtran-10 (Combidex®, Sinerem®,
Guerbet, France), ferumoxytol (Advanced Magnetics, USA),
SHU-555C (Supravist®), and VSOP (very small super-
paramagnetic iron oxide particles) [20, 21].
SH U 555 C has been proposed for first-pass and steady-
state angiography [22]. Such USPIOs have a mean core
particle size of about 3–5 nm and a mean hydrodynamic
diameter of about 20 nm in an aqueous environment.
Relaxivity measurements yield a r1 of 22 s-1 mM-1 and a r2
of 45 s-1mM-1 at 40°C and 20MHz inwater [23]. In a dose-
finding study in healthy volunteers for angiography of the
chest, Reimer et al. [24] used 5, 10, 20, and 40 μmol Fe/kg
during bolus injection @ 0.5 ml/s followed by 20 ml saline
flush (0.9%) at a flow-rate of 3.0 ml/s. CE-MRAs were
acquired at baseline, during first pass, and steady state at 6,
Table 1 Relaxivities of selected contrast agents in water and blood
Water Blood
Short name Generic name Comment Trade name r1* r2* r1* r2*
Gd-DTPA Gadopentetate dimeglumine Non-specific Magnevist 3.3 3.9 4.3 4.4
Gd-BOPTA Gadobenate dimeglumine Weak protein binding Multihance 4.0 4.3 6.7 8.9
MS-325 Gadofosveset trisodium Strong protein binding Vasovist 5.2 5.9 19 37
SH U 555 C Ferucarbotran** USPIO Supravist 13.2 44 14 90
SH L 643 A Gadodenterate** Medium molecular weight N/A 17.3 22 17 22
*Values in L mmol−1 s−1 at 37°C and 1.5 T
**Currently not approved
Adapted from [44]
Fig. 2 Three-step gadofosveset trisodium (0.03 mmol/kg @ 0.8 ml/s)
enhanced angiography of abdominal aorta, iliac arteries, and peripheral
vessels acquired during first pass (a–c) and steady state (d, e).
Maximum intensity projections of first-pass images clearly show
occlusion of left superficial femoral artery (arrow in a and b) and patent
proximal arteries of the lower limb (b). Distal lower limb arteries,
however, are not assessable (c). Targeted maximium intensity
projections of high resolution steady-state angiograms of the calf
clearly show patency of distal posterior (double arrow ind) and anterior
(arrowhead in e) tibial arteries
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12, 18, 24, 30, 36, and 42 min after injection. The IV bolus
injection of SHU 555 Cwas well tolerated by all volunteers;
SH U 555 C showed a dose-dependent increase in SI
enhancement during first pass and steady state. More
recently, phase 3 trials in patients with peripheral arterial
disease and renal vascular disease were completed, but
results have not been published yet. In previous trials first-
passMRAof the aortoiliac vessels was diagnostic at doses of
10, 20, and 40 µmol Fe/kg b.w. For equilibrium CE-
MRA, a dose of 40 µmol Fe/kg b.w. was considered to
be diagnostic. SH U 555 C proved to be a contrast
agent with a high T1 effect suitable for both first-pass
CE-MRA comparable to gadolinium-enhanced angiog-
raphy and high-resolution equilibrium angiography up
to 42 min post-injection (p.i.) [25]. SH U 555 C-
enhanced angiography is feasible at 1.5 and 3 T, but
the signal-to-noise ratio from blood is similar at both
field strengths, which may be ascribed to confounding
T2* shortening [26]. Phase 3 results on SH U 555 C
enhanced angiography in various vascular territories
have not been published yet.
Gadolinium-based BPA
Albumin loaded with Gd-DTPA is a large molecular weight
(92 kDalton) blood pool agent with strong T1/T2
relaxivities of 13.7/18.4 mM−1s−1 and an intravascular
half life of 90 min [27]. This compound, however, has
unfavorable allergenic properties and clearance pathways
and thus cannot be used in humans. Medium molecular
weight BPA such as SHL643A (35 kDalton; 13 l mmol−1 s−1
Gadomer-17, Bayer Schering Pharma, Germany) are cur-
rently under investigation for use in humans, gadofosveset
trisodium (6.4 kDalton; r1/r2=27.1/56 l mM−1 s−1) has
recently been approved. Reduction of molecular weight not
only improves the allergenic properties, but also allows renal
elimination.
Small molecular weight BPA are retained in the blood
pool because they bind non-covalently to plasma proteins.
This reversible binding slows down tumbling of the
molecule and enhances the paramagnetic effectiveness of
gadolinium and allows the administration of lower contrast
agent doses compared with the doses of standard extracel-
lular contrast agents [15]. The dose reduction may be
favorable in patients with reduced kidney function [2, 21].
Moreover, Gadobenate dimeglumine (Multihance® Gd-
BOPTA) has an in vivo blood relaxivity approaching twice
the aqueous solution because it is weakly bound by plasma
proteins. This enhanced relaxivity is favorable for CE-
MRA [22], but this effect is only weak and Gadobenate
dimeglumine is not considered a true BPA.
A stronger noncovalent binding to plasma molecules has
been reported from B-22956/1. The molecular structure of
this agent features a polyaminocarboxylate Gd complex
linked to a deoxycholic acid moiety [28]. This is a
relatively low-molecular-weight gadolinium chelate (1059
Dalton) with high affinity for serum proteins and vascular
containment (94% for a 0.5 mM solution in Seronorm for
human serum albumin, and 90% for pig serum albumin).
With such strong binding, the agent can provide high T1-
relaxivity (∼27 mM-1 s-1 at 20 MHz Larmor frequency in
human serum), which is almost six-fold higher than that of
conventional extravascular contrast agents (4.9 mM-1 s-1
at 20 MHz Larmor frequency in human serum). In
preclinical trials, B-22956/1 was able to maintain blood
T1 below 100 ms for 25 min in pigs [29].
A different concept is based upon the synthesis of an
intermediate size molecule such as Gadomer 17 (SH L 643
A, Schering AG, Berlin, Germany) resembling a synthetic
dendritic gadolinium complex with a molecular weight of
17.45 kDa. The compound is distributed almost exclusively
within the intravascular space, scarcely diffusing into the
interstitial space. The contrast agent has been extensively
tested preclinically and in various clinical trials [30, 31].
Gadofosveset trisodium is a gadolinium-based small-
molecule (975.88 Dalton) contrast agent designed specifi-
cally for MR angiography. Gadofosveset is noncovalently
bound to albumin in human plasma and is primarily
excreted renally. This reversible albumin binding of gado-
fosveset enhances the paramagnetic effectiveness of gado-
linium and allows lower contrast agent doses than are needed
with conventional MR agents (Table 1) [15]. In plasma,
gadofosveset exhibits a relaxivity at 0.5 T that is approxi-
mately six to ten times that of gadopentetate dimeglumine
[15]. Gadofosveset trisodium (Vasovist® MS 325) is
currently the only contrast media with predominant intra-
vascular distribution approved for use in patients.
Gadofosveset trisodium (Vasovist® MS 325) can be
injected as a bolus allowing imaging during first pass
and steady state (Fig. 3). At the recommended dose of
0.03 mmol/kg the safety profile is comparable to that
of other gadolinium contrast agents as reported in the
literature [32].
Potential clinical applications
Coronary arteries
Coronary magnetic resonance angiography remains a
difficult task, although early reports were encouraging
[33]. Today coronary MRA is not a robust technique and
not available for daily routine in patients. One of the most
promising technical approaches, however, is CE-MRAwith
ECG and respiratory-gated, free-breathing, high-resolution,
three-dimensional sequences. Combined cardiac and respi-
ratory gating, however, is time comsuming, thus requiring
prolonged vascular enhancement. Stuber et al. [34] reported
feasibility of coronary angiography enhanced with intravas-
cular gadofosveset trisodium using a double-oblique, free-
breathing, three-dimensional inversion-recovery sequence
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with real-time navigator gating and motion correction.
Acquisition time was 14+/−5 min, resolution was in the
sub-millimeter range with a strong contrast-to-noise ratio. In
six patients, 0.1 mmol/kg of the intravascular contrast agent
gadofosveset trisodiumwas given intravenously followed by
CE-MRA. Images were compared with images obtained
with a T2 prepulse (T2Prep) without exogenous contrast.
The contrast-enhanced images demonstrated a 69% im-
provement in the contrast-to-noise ratio (6.6±1.1 vs. 11.1±
2.5; P<0.01) compared with the T2Prep approach. By using
the intravascular agent, extensive portions (>80 mm) of the
native left and right coronary system could be displayed
consistently with sub-millimeter in-plane resolution. The
intravascular contrast agent leads to a considerable enhance-
ment of the blood/muscle contrast for coronary angiography
compared with T2Prep techniques. The clinical value of the
agent remains to be defined in a larger patient series. Herborn
et al. [35] demonstrated feasibility of SH L 643An enhanced
MR for free breathing coronary angiographywith acquisition
time of 6–8 min, but SH L 643 A is still under investigation
and currently not approved for use in patients.
Peripheral vessels
Peripheral CE-MRA with standard extracellular contrast
agents is well established in the management of peripheral
occlusive disease [36]. Imaging during the arterial phase is
desirable for strong arterial and minimal confounding
background and venous enhancement. But the arterial
phase of extracellular contrast material is short because
rapid extravasation occurs. Various approaches for pro-
longation of the arterial phase, such as venous compression
for imaging of runoff vessels, have been tested [37].
Further extension of the vascular phase is now possible
with BPA during the steady state [16]. Initial clinical
experience with the bolus injectable BPA gadofosveset
trisodium was recently reported from Nikolaou et al. [38].
These investigators assessed the diagnostic accuracy for
detection of 75% or greater stenosis at high-spatial-resolution
multistation CE-MRA with gadofosveset trisodium. Ten
healthy volunteers and ten patients were examined during the
first-pass and steady-state phases of the contrast agent. Vessel
conspicuity on the first-passMR angiograms obtained in both
volunteers and patients was rated as excellent for 93% of
vessels. At steady-state imaging, vessel conspicuity was rated
as excellent or good for 89% of vessels. CE-MRA yielded a
sensitivity of 97% and a specificity of 97% for detection of
significant disease in the lower extremity arteries [38]. The
quality of the high-spatial-resolution lower leg images
acquired during steady state was diminished owing to motion
artifacts related to long acquisition time in a few instances. On
the other hand, small arteries and veins in close vicinity could
be clearly differentiated only at a high spatial resolution of
Fig. 3 Gadofosveset trisodium-
enhanced angiography of
supraaortic vessels during first
pass (a) shows patent right
vertebral artery (arrows). The
(b) left vertebral artery is
occluded because it is not
visible during both the first pass
and steady state
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0.50- or 0.42-mm voxel length. At lower spatial resolution,
venous overlap was a potential diagnostic problem in lower
leg CE-MRA during steady-state phase. As a compromise, a
voxel length of 0.50 mm seems to be acceptable for imaging
the peripheral runoff vessels: It enables clear differentiation of
the arterial and venous structures and an acceptable acqui-
sition time [38].
Renal vessels
Renal CE-MRA is useful [39], but recently a large
prospective multicenter trial revealed that even state-
of-the-art renal CE-MRA with extracellular contrast mate-
rial has limited accuracy [40]. Wilson et al. [41] suggested
improving renal CE-MRA with parallel imaging to
improve image quality and reduce artifacts in first-pass
CE-MRA. Schoenberg et al. [42] further optimized renal
CE-MRA by means of an integrated parallel acquisition
technique with high isotropic spatial resolution of
0.8×0.8×0.9 mm3 in 23 s breath hold and reconstruction
of cross sections orthogonal to vessel axis. Compared to
intravascular ultrasound, the mean percentage of difference
of stenosis measurement was only 13% [42]. The potential
of BPA cannot be fully exploited because the acquisition
time is limited to a breath-hold [38]. Further improvements
may be expected from respiratory-gated steady-state CE-
MRA with BPA.
Carotids
Carotid arteries were studied with gadofosveset trisodium
by Bluemke et al. [43]. Within this phase 2 trial 50 carotid
arteries in 26 patients were imaged with 3D-spoiled GRE
MRA at 5 and 50 min after injection of 0.01, 0.03, or
0.05 mmol per kg. Conventional contrast catheter angiog-
raphy was used as the standard of reference. Overall
accuracy for carotid CE-MRA performed during steady-
state conditions approximately 5 min after injection was
high (88%–100%) at 0.03 and 0.01 mmol/kg as determined
by blinded reading [43]. In a recent study with a series of
ten healthy volunteers and ten patients the carotid arteries
were imaged with gadofosveset trisodium during first pass
and at steady state. Two patients had significant lesions on
ultrasound; both lesions were clearly identified on CE-
MRA [38]. At steady-state image quality was assessed in
isotropic voxels of 0.5, 0.8, and 1.0 mm. Most interest-
ingly, the image quality was best at a voxel size of 0.8 mm
(acquisition time=40 s). On higher resolution angiograms
(0.5 mm), images were degraded by pulsation and motion
artifacts related to the increasing acquisition times from
40 s (0.8 mm) to 1 min 41 s (0.5 mm) [38].
Conclusion
The group of BPA comprises ultrasmall supraparamagnetic
iron-oxide particles, gadolinium-based macromolecules,
and gadolinium-based small molecules with strong revers-
ible binding to plasma proteins. Gadofosveset is the only
currently approved BPA. It has interesting properties for
CE-MRA since it allows for first-pass angiography similar
to standard extracellular compounds, but with higher
relaxivity. An additional feature is the steady-state phase
enabling high-resolution angiography or double-gated
angiography of coronary arteries with complex motion
pattern.
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